Evidence map›Paper›PMID 26149185›Full record

ArticleClinical and experimental immunology2015

Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.

Z Reyes-Castillo, C A Palafox-Sánchez, I Parra-Rojas, G E Martínez-Bonilla, S del Toro-Arreola, M G Ramírez-Dueñas, G Ocampo-Bermudes, José F Muñoz-Valle

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Clinical and experimental immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Frontiers in immunology · 2021
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Z Reyes-CastilloResearch Institute in Biomedical Sciences, Department of Medical Clinics, CUCS, Universidad De Guadalajara, Guadalajara, Jalisco.
C A Palafox-SánchezResearch Institute in Biomedical Sciences, Department of Medical Clinics, CUCS, Universidad De Guadalajara, Guadalajara, Jalisco.
I Parra-RojasAcademic Department of Chemistry and Biologic Sciences, Universidad Autonoma De Guerrero, Chilpancingo, Guerrero.
G E Martínez-BonillaDivision of Rheumatology, Hospital Civil De Guadalajara 'Fray Antonio Alcalde', Guadalajara, Jalisco.
S del Toro-ArreolaInstitute of Chronic and Degenerative Diseases, Department of Molecular Biology and Genomics, CUCS, Universidad De Guadalajara, Guadalajara, Jalisco, Mexico.
M G Ramírez-DueñasResearch Institute in Biomedical Sciences, Department of Medical Clinics, CUCS, Universidad De Guadalajara, Guadalajara, Jalisco.
G Ocampo-BermudesResearch Institute in Biomedical Sciences, Department of Medical Clinics, CUCS, Universidad De Guadalajara, Guadalajara, Jalisco.
José F Muñoz-ValleResearch Institute in Biomedical Sciences, Department of Medical Clinics, CUCS, Universidad De Guadalajara, Guadalajara, Jalisco.
Hospital Civil de Guadalajara · MXUniversidad Autónoma de Guerrero · MXUniversidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies against cyclic citrullinated peptides (anti-CCP) are widely used for diagnosis of rheumatoid arthritis (RA). We performed a comparative analysis of antibodies targeting the citrullinating enzyme peptidylarginine deiminase type 4 (anti-PAD4) and mutated citrullinated vimentin (anti-MCV) with anti-CCP autoantibodies in RA patients and examined their relationships with clinical parameters, cytokine profiles and the PADI4 gene. Autoantibodies were examined by enzyme-linked immunosorbent assay (ELISA) in sera of 170 RA patients and 103 controls. Cytokine profiles were measured using a multiplex system. PADI4 polymorphisms (89 G > A, 90 T > C and 92 G > C) were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Anti-PAD4, anti-MCV and anti-CCP autoantibodies were detected in 24, 61 and 74% of RA patients, respectively. Positive correlations were observed between anti-PAD4 and disease duration; anti-CCP and erythrocyte sedimentation rate (ESR); anti-MCV and ESR and C-reactive protein. Anti-MCV antibodies were associated with high disease activity score 28 (DAS-28) in early RA. Concentrations of T helper type 1 (Th1) [tumour necrosis factor (TNF)-α, interleukin (IL)-12, IL-2, IL-1β], Th2 (IL-4, IL-6, IL-10, IL-13) and Th17 (IL-17) cytokines were higher in RA than in controls. Th2 and, to a lesser extent, Th1-related cytokines, showed positive correlations with anti-MCV and anti-CCP. The GTG haplotype in PADI4 was associated with anti-CCP and anti-MCV, but not anti-PAD4 antibodies. In conclusion, anti-PAD4 antibodies are detected mainly in established RA, which is in contrast to the early detection of antibodies against citrullinated peptide/proteins (ACPAs). Among autoantibodies, anti-MCV appear to perform better as markers of disease activity. Furthermore, anti-CCP and anti-MCV are associated genetically with the citrullinating enzyme PAD4 and are related strongly to Th1 and Th2 cytokines, suggesting a feed-forward loop between cytokines and ACPA production.

Indexed as

AdultArthritis, RheumatoidAutoantibodiesBlood SedimentationCitrullineCytokinesEnzyme-Linked Immunosorbent AssayFemaleGene FrequencyGenotypeHumansHydrolasesMaleMiddle AgedMutant ProteinsPeptides, CyclicAutoantibodiesCitrullinecyclic citrullinated peptideCytokinesHydrolasesMutant ProteinsPADI4 protein, humanPeptides, CyclicProtein-Arginine DeiminasesProtein-Arginine Deiminase Type 4VimentinACPAcitrullination, disease activityPADI4rheumatoid arthritis

Identifiers

PMID26149185
PMCPMC4608501
OpenAlexW1901640178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.